Winton Group’s Turning Point Therapeutics, Inc. Common Stock TPTX Stock Holding History

Winton Group’s Portfolio TPTX Stock Details TPTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-13,887	Closed	-$1.04M	–	1127
2022 Q2	$1.04M	Buy	13,887 +2,477	+22%	+$110K	0.06%	473
2022 Q1	$306K	Buy	11,410 +1,849	+19%	+$62.1K	0.02%	811
2021 Q4	$456K	Sell	9,561 -933	-9%	-$41.7K	0.03%	703
2021 Q3	$697K	Buy	10,494 +1,737	+20%	+$124K	0.04%	691
2021 Q2	$683K	Sell	8,757 -677	-7%	-$50K	0.04%	743
2021 Q1	$892K	Sell	9,434 -1,334	-12%	-$159K	0.05%	533
2020 Q4	$1.31M	Sell	10,768 -27,586	-72%	-$3.02M	0.09%	272
2020 Q3	$3.35M	Buy	+38,354	New	+$2.67M	0.11%	279

Winton Group's TPTX Position: Q3 2022 in Review

Winton Group sold out of Turning Point Therapeutics, Inc. Common Stock (TPTX) in Q3 2022, closing a stake of 13,887 shares — an estimated $1.04M sold.

Winton Group first reported a position in TPTX in Q3 2020 and held it in 8 quarters. The position peaked at $3.35M in Q3 2020. 0 funds tracked by Wall St. Rank hold TPTX as of Q3 2022.

Winton Group reported no remaining Turning Point Therapeutics, Inc. Common Stock position as of Q3 2022 after selling out during the quarter.
Winton Group sold 13,887 Turning Point Therapeutics, Inc. Common Stock shares in Q3 2022, an estimated $1.04M.
Winton Group first reported a position in Turning Point Therapeutics, Inc. Common Stock in Q3 2020 and held it in 8 quarters.
Winton Group's Turning Point Therapeutics, Inc. Common Stock position peaked at $3.35M in Q3 2020.
0 funds tracked by Wall St. Rank held Turning Point Therapeutics, Inc. Common Stock as of Q3 2022.

Based on Winton Group's 13F filing for Q3 2022, filed 10 Nov 2022.